Early virological failure with cabotegravir/rilpivirine-Reference-Cited by-同舟云学术

Early virological failure with cabotegravir/rilpivirine

Published:2024-02-22 Issue:5 Volume:79 Page:1193-1194
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Bailón L¹²³^ORCID,Sábato S³^ORCID,Coll J⁴⁵,Santos J R¹³^ORCID,Miranda C³,Puig T⁴,D´Avolio A⁶,Paredes R¹³^ORCID,Moltó J¹³⁷^ORCID,Negredo E¹³

Affiliation:

1. HIV-Unit Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol , Badalona , Spain

2. Department of Medicine, Autonomous University of Barcelona , Catalonia , Spain

3. Fundació Lluita Contra les Infeccions , Badalona, Barcelona , Spain

4. IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol , Badalona, Barcelona , Spain

5. Projecte dels Noms-Hispanosida , BCN-Checkpoint, Barcelona , Spain

6. Department of Medical Sciences, University of Turin , Turin , Italy

7. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain

Funder

Fundació Lluita Contra les Infeccions

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/jac/article-pdf/79/5/1193/57368051/dkae044.pdf

Reference10 articles.

1. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023;Ambrosioni;HIV Med,2023

2. Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials;Rizzardini;J Acquir Immune Defic Syndr,2020

3. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2 M, a randomized, open-label, phase 3b, noninferiority study;Overton;Clin Infect Dis,2023

4. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study;Garris;J Int AIDS Soc,2022

5. Effectiveness of injectable long-acting cabotegravir and rilpivirine for the treatment of HIV-1: results from the Dutch ATHENA national observational cohort;Jongen

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine;Journal of Antimicrobial Chemotherapy;2024-07-27